This Spotlight Session will review new agents in development for the treatment of IgA nephropathy, including the dual BAFF/APRIL antagonist, povetacicept. The presentation will focus on (1) how the various mechanisms of action being explored target different aspects of the multi-hit model of IgA nephropathy pathogenesis, (2) the relative pros and cons of targeting early versus late hits , and (3) how inhibition of both BAFF and APRIL may provide disease-modifying potential (including initial findings from the povetacicept RUBY-3 trial).